Beijing Bohui Innovation Biotechnology Group Co 300318.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
4.45
-1.33%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Bohui Innovation Biotechnology Group Co
Its shares trade on Shenzhen under the ticker 300318.SZ. It has been listed since 23 May 2012. In the fiscal year to 31 December 2025, it reported revenue of CN¥824.6m and a net loss of CN¥91.9m. At that date it held total assets of CN¥4.30bn and shareholders' equity of CN¥1.29bn.
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and service of clinical laboratory analysis products. The company is headquartered in Beijing, Beijing. The company went IPO on 2012-05-23. The firm operates two major reporting segments. The Inspection and Testing segment is mainly engaged in the research and development, production and sales of inspection instruments and inspection reagents. The firm's products for medical institutions mainly involve in vitro diagnostic testing, including human trace element testing and human papillomavirus (HPV) testing. The firm's testing equipment for non-medical institutions is mainly small mass spectrometers and related products. The Biological Products segment is mainly blood products, which can be divided into products such as albumin, immunoglobulin, coagulation factors and vaccines. The firm distributes its products within the domestic market and to overseas market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 23 May 2012
- Employees
- 1,652
- Website
- bohui-tech.com ↗
Leadership
Pay as last reported
- Mr. Zhiwei ShenChairman of the Board, General Manager, since 2020
- Ms. Jia LiuChief Financial Officer
- Mr. Haifeng DongDeputy General Manager, Secretary of the Board, Director, since 2020CN¥539,000
- Mr. Wei WangDeputy General Manager, Director, since 2020CN¥1.2m
- Ms. Shuhui NiuDeputy General ManagerCN¥869,100
- Mr. Lei ZhangDeputy General Manager, since 2020CN¥858,900
- Ms. Yan JiangDirector, since 2020CN¥1.2m
- Ms. Yong ShenDirector
- Mr. Chenglin ZengDirector
- Mr. Jun BanIndependent DirectorCN¥100,000
- Mr. Jun YinIndependent Director
- Ms. Xiaosu ZhangIndependent DirectorCN¥100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beijing Bohui Innovation Biotechnology Group Co Ltd has 1652 employees and operates in the Health Care sector.
- The Inspection and Testing segment focuses on in vitro diagnostic testing including HPV testing and human trace element testing.
- The Biological Products segment offers blood products like albumin, immunoglobulin, and coagulation factors.
Weaknesses
- The company's products are distributed only within the domestic market and to overseas market.
- The firm's IPO was on 23 May 2012, which is a fixed historical date.
- Beijing Bohui Innovation Biotechnology Group Co Ltd is headquartered in Beijing, Beijing.
Opportunities
- The company can expand its overseas market presence beyond current distribution channels.
- The Inspection and Testing segment can develop new products for small mass spectrometers.
- The Biological Products segment can explore new vaccine development opportunities.
Threats
- The company faces competition from other Health Care sector firms in China.
- The firm's reliance on domestic market distribution may limit growth potential.
- The company's products are subject to regulatory changes in the Health Care industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.